Velocity is collaborating with Merck to enhance the way trial insights are shared within Merck and across Velocity sites worldwide. Through fast-response data exchange, we’ve developed the Velocity Insight Platform (VIP), a dynamic dashboard that provides actionable metrics to optimize site activities. A huge thank you to the data team at Merck for their dedication … Read more
Nadege Gunn, MD, CPI, DABOM, FAASLD, has been named a Fellow of the American Association for the Study of Liver Diseases (AASLD)! This designation is the highest honor awarded to AASLD members and recognizes Dr. Gunn’s exceptional contributions to liver disease research and clinical care. In addition to her impact on the broader research community, … Read more
Clinical trials have been steadily leaving the UK for years. In 2021, just 2.2% of patients recruited to global trials were from the UK. By contrast, France, which has a similar population size, accounted for 3.9% that year. That’s not to say we don’t still have some clout (the UK ranks fourth globally for Phase … Read more
Charles Eger, MD, contributed to new research on a combination vaccine intended to provide protection against both seasonal flu and COVID-19 in a single shot. Early results from the Phase 1/2 trial show that the vaccine is well-tolerated and induces strong immune responses, potentially paving the way for a more convenient approach to respiratory virus … Read more
Luke Boylan, MBChB, MBA, Principal Investigator at Velocity in North London, recently attended the Parexel Site Alliance Network event. This collaborative gathering included NHS/NIHR-affiliated sites and other commercial research organizations, providing an invaluable opportunity to discuss the evolving landscape of clinical trials in the U.K. Dr. Boylan’s key takeaways from the event: Regulatory Improvements: There … Read more
Paul Evans sat down with Patricia Leuchten on the Leaders & Legends podcast, where they discussed the state of research sites and the broader industry. Listen now to hear Paul’s thoughts on: The evolution of clinical research sites and what’s ahead for the industry. Challenges in patient recruitment and the role of site-based technology. His … Read more
Women’s health remains one of the most overlooked and underrepresented areas in clinical research, often leading to gaps in treatment and understanding. Similar to obesity research, disorders relating to reproductive health include symptoms that are highly stigmatized and patients can be reluctant to seek treatment or join clinical trials. This is why Velocity set up … Read more
Velocity’s team contributed to the new Association of Clinical Research Professionals (ACRP) comprehensive whitepaper, titled ‘Responsible Oversight of Artificial Intelligence for Clinical Research Professionals.’ The development of our VISION technology has coincided with the proliferation of AI and large language models (LLMs). For recruitment purposes, these tools have improved patient-trial matching, automated outreach, and enabled … Read more
Robert Cupelo, MD, Principal Investigator in Syracuse, NY, shares his firsthand insights into the evolving landscape of Alzheimer’s treatment. Nearly two years after the FDA’s approval of lecanemab (Leqembi), and with the subsequent approval of donanemab (Kisunla), researchers are making crucial steps forward in the fight against disease progression and for disease prevention. In this … Read more
A new Fierce Biotech article features insights from Paul Evans on what to expect for clinical research in 2025. Topics include rising costs and uncertain regulations, as well as the continued emergence of site networks, AI-driven efficiency (with technology built “by trial sites, for trial sites”), and enhanced diversity initiatives. Read the article here: https://www.fiercebiotech.com/cro/clinical-trials-industry-set-uncertain-interconnected-2025-according-velocity-clinical-research